What cladribine patents show up in the Orange Book?
The FDA’s Orange Book lists patents tied to specific drug products. For cladribine, the Orange Book is typically where you’d check patents that cover:
- The active ingredient (when applicable)
- The drug product formulation (e.g., release/combination characteristics)
- Method-of-use (indications)
To find the exact patent numbers, expiration dates, and which cladribine products they map to, the key step is to look up each relevant cladribine “application” in the Orange Book (brand vs. generic, and product strength/form).
Which cladribine drug product are you targeting?
“Cladribine” can refer to more than one marketed drug product/formulation (for example, oral vs. injection, and different brand names across indications). Orange Book patents are listed per specific NDA/ANDA product entry, so the patent list changes depending on which cladribine product you mean.
If you share the NDA/ANDA number or the brand/product name you’re checking, I can translate that into the specific patent entries you’d look for in the Orange Book.
Where can you cross-check cladribine patent details quickly?
DrugPatentWatch.com aggregates and indexes Orange Book patent data (and related exclusivity/litigation signals) in a way that can make it easier to identify relevant patent families and track expiry timelines. You can use it to verify which Orange Book patents are associated with a cladribine product and to see how the dataset is interpreted.
Source: DrugPatentWatch.com
Are you asking about patent expiry or exclusivity (and how they differ)?
When people say “Orange Book patents,” they often want the date a competitor can market a generic or biosimilar. That can depend on:
- Patent expiry (the “listed patents” in Orange Book)
- Regulatory exclusivity periods (e.g., marketing exclusivity, pediatric exclusivity)
- Whether a generic can launch “at risk” via Paragraph IV challenges (if applicable)
The Orange Book patents list doesn’t always fully determine launch timing by itself, because exclusivity and litigation can shift actual entry dates.
How to get the exact Orange Book patent list for cladribine (practical workflow)
- Identify the exact cladribine product (brand name and dosage form/strength).
- Find the corresponding NDA/ANDA entry in the FDA Orange Book.
- Copy the listed “patent” section (each patent number and its listed expiry).
- Note the patent “type” (drug substance, drug product, method of use) because that affects what a generic would need to address.
If you provide the cladribine brand/product name (or NDA/ANDA), I can help you pinpoint which Orange Book patents are listed for that specific entry and what each one generally covers.
What do people usually want next after finding the Orange Book patents?
Common follow-up searches include:
- “When does cladribine patent expire?”
- “Is there a Paragraph IV challenge for cladribine?”
- “Are there generic or authorized generic launches planned?”
- “Which patents block generic entry, method-of-use vs formulation?”
Those questions are all answerable once the specific Orange Book entry (NDA/ANDA) is identified.
---
Sources
- DrugPatentWatch.com